Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma.
Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara N, Yoshimoto T, Nakagawa Y, Fukuyama T, Oya M, Shinohara N, Uemura H, Tsuzuki T. Uemura M, et al. Among authors: nakagawa y. Int J Clin Oncol. 2021 Nov;26(11):2085-2086. doi: 10.1007/s10147-021-02008-5. Int J Clin Oncol. 2021. PMID: 34449010 Free PMC article. No abstract available.
Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study.
Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H. Tsuzuki T, et al. Among authors: nakagawa y. Pathology. 2023 Feb;55(1):31-39. doi: 10.1016/j.pathol.2022.07.013. Epub 2022 Sep 20. Pathology. 2023. PMID: 36241555 Free article.
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M. Tamada S, et al. Among authors: nakagawa y. Int J Clin Oncol. 2023 Feb;28(2):289-298. doi: 10.1007/s10147-022-02256-z. Epub 2022 Dec 19. Int J Clin Oncol. 2023. PMID: 36534263 Free PMC article.
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
Yamamoto N, Kitano S, Koyama T, Ikeda M, Mizugaki H, Narikiyo T, Yamaguchi Y, Ishida T, Takubo R, Ogami C, Sekiya M, Nakagawa Y, Kuboki Y. Yamamoto N, et al. Among authors: nakagawa y. J Immunother Cancer. 2024 Jul 24;12(7):e009262. doi: 10.1136/jitc-2024-009262. J Immunother Cancer. 2024. PMID: 39053945 Free PMC article. Clinical Trial.
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.
Kudo M, Tsuchiya K, Shao YY, Finn RS, Galle PR, Ducreux M, Cheng AL, Yamashita T, Koga H, Take R, Yamada K, Asakawa T, Nakagawa Y, Ikeda M. Kudo M, et al. Among authors: nakagawa y. Liver Cancer. 2023 Nov 28;13(4):401-412. doi: 10.1159/000535501. eCollection 2024 Aug. Liver Cancer. 2023. PMID: 39114762 Free PMC article.
4,066 results